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We evaluated the expression and amplification of cyclin L1 (CCNL1) gene, a potential oncogene localised in the commonly amplified
3q25–28 region, in human head and neck squamous cell carcinomas (HNSCCs). Overexpression was observed in 55 out of 96 cases
(57%) and amplification in nine out of 35 tumours (26%) with no relationships to the clinico-pathological parameters. The Cyclin L1
antibody we developed labels nuclear speckles in tumour cells compatible with a role for CCNL1 in RNA splicing.
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Definition of the genetic changes associated with head and neck
squamous cell carcinoma (HNSCC), in particular by comparative
genomic hybridisation (CGH), pinpointed gain of the 3q chromo-
some as one of the most frequent abnormalities (Bockmuhl et al,
2000). We demonstrated that the 3q25–28 region is a consistent
site of gain in early HNSCC (Redon et al, 2001), and suggested that
the gain is associated with shortened disease survival (Redon et al,
2001). This association was confirmed in other larger studies
underlying the importance of this region in the development of
HNSCC (Bockmuhl et al, 2000; Ashman et al, 2003, and
publications therein). Several putative oncogenes from the 3q25–
28 region have been proposed to be potential targets of
amplification, including PIK3CA (Estilo et al, 2003), SCCRO (Estilo
et al, 2003), p63 (Thurfjell et al, 2005), and cyclin L1 (CCNL1),
which we showed by microarray-based CGH to be amplified in an
HNSSC cell line (Redon et al, 2002). The main a isoform of Cyclin
L1 contains an RS domain (Ser–Arg rich proteins) that may confer
splicing activity to cyclin L1 (Dickinson et al, 2002). CCNL1 is an
immediate early gene induced by several growth factors (Berke
et al, 2001) that may regulate G0–G1 cell-cycle progression (Redon
et al, 2002 and publications herein).
In the present study, we measured CCNL1 gene expression in 96
human HNSCCs by real-time quantitative PCR. CCNL1 gene copy
number was evaluated to examine the relationship between RNA
expression and DNA copy number alterations. The relationship
between CCNL1 gene alterations and pathological features as well
as clinical outcome is reported. Finally, the localisation of the
cyclin L1 protein was determined by immunohistochemistry on
normal and neoplastic head and neck tissues.
MATERIALS AND METHODS
Patients and samples
A total of 96 HNSCC samples were selected from consenting
patients who underwent surgery as first treatment, without
previous radiation or chemotherapy. Matched normal mucosa
samples were obtained for 82 cases by resection at least 5cm from
the tumour. They were immediately frozen and stored in liquid
nitrogen. Clinico-pathological features are summarised in Table 1
using the UICC TNM system. The mean clinical follow-up was 62
months (range 0.5–199).
Cyclin L1 gene expression and copy number
Total RNA isolation and cDNA preparation were performed as
described previously (Redon et al, 2001). Genomic DNA was
isolated by phenol/chloroform extraction. CCNL1 gene amplifica-
tion and expression were assessed by quantitative PCR performed
with the LightCycler system, using LC Fast start DNA master SYBR
green I mixture, and version 3.0 software (Roche Diagnostics,
Meylan, France).
The specific oligonucleotide primers, designed by Primer3
software, were: (a) for gene expression analysis: CCNL1, 50-ACT
CCAAGCCCCCTGATCCT-30 and 50-TGGCAACGGAATCTGAAGT
G-30, which amplify the a and b isoforms; the ubiquitous gene
RPLP0, 50-GAAGGCTGTGGTGCTGATGG-30 and 50-CCGGATAT
GAGGCAGCAGTT-30; (b) for gene amplification analysis: CCNL1,
50-TAGGCGGAGTCGATCTGGAA-30 and 50-CCATGGTGCTTGCT
TTTATGG-30; and two genes located on respectively chromosome
15q15–21 and 11p15, CAPN3 (calpain3/p94), 50-GCTGGTAGGA
GACCCCCAAG-30 and 50-CCACAGATGCGCTAATGACG-30, HBB
(beta-globin), 50-GAAGAGCCAAGGACAGGT-30 and 50- TGGTGT
CTGTTTGAGGAAGC-30.
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sIn order to obtain for each gene results in ng for expression and
copy number, respectively, calibration curves were constructed
using pools of cDNAs from 10 normal head and neck tissue
samples and DNA from peripheral blood samples from 10 healthy
individuals. CCNL1 gene expression was evaluated for 96 tumours
and 82 corresponding normal tissues using the mean value from
three independent experiments. The relative CCNL1 gene expres-
sion level was calculated by successive normalisation to the RPLP0
(Ribosomal phospho-protein P0) internal control and then to the
mean expression of all the normal tissue samples. A relative value
X1.7 was considered to represent overexpression. Cyclin L1 copy
number changes were analysed for 35 tumours and 14 normal
samples by independent duplicate PCR reactions with two DNA
inputs, 6 and 2ng. Copy number values for a tumour sample were
calculated in relative units adjusted to the mean values of CAPN3
and HBB internal controls. The results were expressed as fold
differences in target gene copy number in tumours relative to
normal samples. A relative value X1.5 was considered to represent
amplification.
Cyclin L1 protein expression
Cyclin L1 protein expression was assessed by immunohisto-
chemistry, using a mouse monoclonal antibody raised against the
peptide SKHHGGRSGHCRHRR. This sequence is found only at the
C-terminal of the isoform a. For retrieval, 3mm de-waxed sections
were pressure-cooked for 3min in 0.1 M citrate buffer pH 6.0. They
were incubated overnight at 41C with a 1/1000 dilution of the
primary antibody, and revealed by the avidin-biotin peroxydase
complex method (DAKO labelled streptavidin-biotin LSAB).
Negative controls lacked the primary antibody.
Statistics
Associations with clinico-pathological features and CCNL1 expres-
sion or amplification were analysed at the 5% significance level
using the ANOVA or Kruskal Wallis tests where appropriate.
Survival was analysed by the Kaplan–Meier method and the log-
rank test with MedCalc software (MedCalc, Belgium).
RESULTS
Real-time quantitative PCR analysis of 96 HNSCCs and 82 of their
counterpart normal tissues showed that Cyclin L1 gene expression
levels were significantly different between tumours and normal
tissue samples (T-test; Po0.0001) (Figure 1A). Overexpression was
found in 55 tumours (57%). Expression levels in tumours were not
significantly associated with their clinico-pathological features
(tumour site, size or differentiation, lymph node involvement,
Table 1).
CCNL1 gene amplification, evaluated in 35 HNSCCs, was
observed in 26% of the tumours and does not exceed three-fold
(relative to the mean of 14 normal tissue samples) (Figure 1B).
Overexpression was observed in almost all tumours with
amplification (seven out of nine cases with amplification), while
lack of overexpression in tumours without amplification was
observed in 65% (17 out of 26) of the cases, suggesting correlation
between CCNL1 overexpression and amplification (Table 2, Fish-
er’s test P¼0.049). Amplification was not statistically related to
the clinico-pathological features of the tumours (not shown).
Disease progression was observed for 60 patients. No statisti-
cally significant relationship was observed between either CCNL1
overexpression or amplification and crude survival or relapse-free
survival of the patients, even for tumours with high expression
levels (highest quartile, data not shown). Gene amplification
evaluation was mainly performed on tumours of pharyngeal origin




























































































Figure 1 CyclinL1 gene alterations assessed by quantitative real-time
PCR. (A) Relative cyclin L1 gene expression level in 96 head and neck
tumours (T) and 82 normal tissues (N); T-test, Po0.0001, mean value for
N: 1.00 by construction (95% CI¼0.9–1.09), for T: 2.01 (95% CI¼1.8–2.2),
(B) Relative cyclin L1 gene copy level in 14 normal (N) and 35 tumour
tissues (T); T-test, P¼0.02, mean value for N: 1.00 by construction (95%
CI¼0.95–1.05), for T: 1.26 (95% CI¼1.12–1.39).
Table 1 Relation between Cyclin L1 gene expression and clinico-




Number of cases (%) P-value*
Localisation
All 96 55 (57%)
Hypopharynx 64 38 (59%)
Oropharynx 20 13 (65%) 0.245
Oral cavity 12 4 (33%)
Tumour size
T1 12 7 (58%)
T2 49 33 (67%) 0.065
T34 35 15 (43%)
Lymph node involvement
N0 44 22 (50%) 0.59
N+ 52 33 (63%)
Tumour differentiation
Well 30 13 (43%) 0.34




*ANOVA test on relative expression values.
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samplification, no association with either histo-clinical features or
survival outcome was observed.
We developed a monoclonal antibody against the long form of
the protein (a isoform) and used it for Western blotting
(Figure 2A). The nuclear staining (Figure 2B) observed by
immunocytofluorescence is similar to that observed in COS cells
transfected with flagged CCNL1 and revealed by an anti-FLAG
antibody (Berke et al, 2001). In tumours, Cyclin L1 staining is
mostly restricted to the nuclei of the epithelial cells with discrete
additional cytoplasmic staining in some cells (Figure 3). No
staining was observed in stromal cells. Heterogeneous staining was
observed throughout the tumour sections and between different
tumours. Normal epithelium displays weak nuclear staining of the
parabasal cells (arrow).
DISCUSSION
In this large series of HNSCCs, we observed a high prevalence of
CCNL1 gene overexpression, occurring in more than half of the
tumours. CCNL1 gene copy number was increased in 26% of the
cases, in accordance with the 34% of gains reported by FISH
analysis with a CCNL1 gene probe (Sticht et al, 2005). Further-
more, we demonstrated gene overexpression in most HNSCCs with
amplification of the CCNL1 gene, supporting the hypothesis that
its expression level partly follows a gene dosage effect. However,
CCNL1 overexpression was also detected in 34% (nine out of 26) of
tumours without CCNL1 gene amplification, showing that other
transcriptionnal regulation factors are involved. Similar discre-
pancy between overexpression and amplification has been
reported for other oncogenes. For example, overexpression of
cyclin D1 in oral squamous cell carcinomas is twice as frequent as
CCND1 amplification (Miyamoto et al, 2003).
A recent study, comparing DNA copy number to gene
expression levels over large chromosomal regions in HNSCCs,
concludes that chromosomal alterations affect the expression of
many genes (Masayesva et al, 2004). The discrimination between
genes that are important for tumour evolution from bystander
ones within regions of copy number changes remains complex.
Only some of these overexpressed genes may be important for
tumorigenesis, and identifying them replies on several clues such
as gene amplification/expression correlations, functional charac-
terisation or association with clinical features. Multiple genes
within the commonly gained 3q region appear to be relevant for
head and neck cancer progression. The gain of chromosomal
region 3q25–28 is associated with aggressive clinical behavior
(Bockmuhl et al, 2000; Singh et al, 2002; Ashman et al, 2003).
Overexpression of several genes at 3q26 have prognostic value,
including SCCRO in oral tongue (Estilo et al, 2003) and ZASC1 in
oesophageal (Imoto et al, 2003) tumours. Recently, high levels of
CCNL1 gene amplification, assessed by FISH (48signals/cell) have
been found in 3% of a large HNSCC series and were shown to be
associated with shorter survival (Sticht et al, 2005). In our series,
high-level amplification was not found, and neither CCNL1 gene
amplification nor overexpression was associated with unfavour-
able tumour phenotype. Difference concerning amplification
between both studies may be due to sampling differences since
our population is mainly composed of tumours derived from
pharynx (86 %) while Sticht et al investigated mostly oral cavity
tumours.
Inappropriate expression of multiple genes at the 3q25–28
chromosomal locus, including CCNL1, could contribute to disease
progression, providing growth advantage by additive effects in
different cellular pathways. CCNL1 (isoform a) could be a
regulator of the G0 to G1 cell-cycle transition. Analysis of the
relationships with cell cycle regulators specially relevant in head
and neck cancers, such as Cyclin D1 or growth factors, would be of
interest. CCNL1 may have also a role in transcription or RNA
splicing, since it colocalises within nuclear speckles with splicing
factors SC-35 and 9G8 in cells transfected by cyclin L1 isoform a







Figure 2 Validation of anti Cyclin L1 alpha mouse monoclonal antibody.
(A) Western blot validation. The monoclonal antibody was validated with a
Cal-27 HNSCC cell line protein extract. It detects a protein (indicated by
the arrow) of size between 54 and 80kDa, compatible with predicted size
of CCNL1 alpha (526 aa, around 60kDa). Molecular marker sizes are
indicated on the left. (B) Immunocytofluorescence validation. The CCNL1
alpha antibody (red colour) labels nuclear speckles of the two transfected
COS cells presented. No cytoplasmic staining was observed. Blue colour
corresponds to DAPI staining of nuclei. This pattern is identical to a
previously published localisation using an anti-FLAG labelling on transfected
COS cells (Berke et al, 2001).
Figure 3 Immunohistochemical detection of cyclin L1 protein in normal
and neoplastic head and neck tissues from HNSCC patients. (A) Slight
positive staining of parabasal cells (arrow) of normal epithelium from the
upper aero-digestive tract (Bar represents 200mm). (B) Strong nuclear
staining of tumour cells in a moderately differentiated head and neck
tumour tract (bar represents 50mm); (C) enlargement of image B, positive
staining of speckles in the nuclei tract (bar represents 25mm).
Table 2 Relationship between cyclin L1 gene amplification and
expression in head and neck SCC
Not amplified Amplified Total
No overexpression 17 2 19
Overexpression 9 7 16
Total 26 9 35
Fisher’s test, P¼0.0497. SCC, squamous cell carcinoma.
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snuclei of malignant cells of head and neck tumours, by histological
immunodetection using our antibody. CCNL1 overexpression may
modify the splicing pattern of specific genes, in particular genes
involved in apoptosis for which splicing variants have been shown
to have agonist or antagonist effects (Schwerk and Schulze-
Osthoff, 2005). Altogether, these findings suggest that cyclin L1
might have a role in the RNA processing complex and could
participate to tumour progression of HNSCC. It thus remains of
interest to investigate further the physiological functions of cyclin
L1 and its link to head and neck carcinogenesis.
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